Clarification: Preferred infliximab strategy for adult Blue Cross' PPO (commercial) members

Blue Cross Blue Shield of Michigan and Blue Care Network use the web-DENIS message platform to communicate information to providers. The intent of these messages is to provide timely communication on an easy-to-access platform, giving both insight and transparency to our initiatives and programs.

Each web-DENIS message includes a "Start date" and an "End date" to let readers know when each message was posted and how long it will be available. These dates don't pertain to or relate to the information in the message. For example, the dates do not relate to initiative start dates.

On July 30, 2019, we posted a web-DENIS message titled "Effective November 1, Inflectra^® is the preferred infliximab product for adult Blue Cross' PPO commercial members." The message had a start date of July 30, because that's the date on which we posted it. To avoid any confusion regarding the start date of the message and the start date of the Inflectra initiative, we promptly removed the message and we're working to optimize our web-DENIS messages to ensure clarity and maximize understanding.

You can find information related to our infliximab strategy for adult Blue Cross' PPO (commercial) members on this website. Look for the news item titled "Effective November 1, Inflectra^® is the preferred infliximab product for adult Blue Cross' PPO (commercial) members" under the July 2019 heading.

Please note that, on August 8, we also revised and re-posted the original web-DENIS message titled "Effective November 1, Inflectra^® is the preferred infliximab product for adult Blue Cross' PPO (commercial) members" regarding the Inflectra initiative.

Posted: August 2019
Line of business: Blue Cross Blue Shield of Michigan